Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer

Chaoyue Su, Hui Wang, Yunru Liu, Qiaoru Guo, Lingling Zhang, Jiajun Li, Wenmin Zhou, Yanyan Yan, Xinke Zhou, Jianye Zhang

Research output: Contribution to journalReview articlepeer-review

21 Citations (Scopus)


Currently, immunotherapy has shown great efficacy in clinical trials, and monoclonal antibodies directed against immune checkpoint PD-1/PD-L1 have shown encouraging results in first-line or second-line treatment of non-small cell lung cancer patients. Meanwhile, anti-PD-1/PD-L1 immune checkpoint drugs combined with other treatments, such as chemotherapy, targeted therapy as well as anti-CTLA-4 checkpoint therapy, are considered an attractive treatment with higher efficacy. However, toxicity associated with PD-1/PD-L1 blockade is worth attention. Understanding the adverse effects caused by anti-PD-1/PD-L1 immunosuppressive agents is vital to guide the clinical rational use of drug. In this review, we summarized the adverse effects that occurred during the clinical use of anti-PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer and discussed how to effectively manage and respond to these adverse reactions.

Original languageEnglish
Article number554313
JournalFrontiers in Oncology
Publication statusPublished - Sept 17 2020
Externally publishedYes


  • adverse effects
  • immune checkpoint inhibitor
  • immunotherapy
  • non-small cell lung cancer
  • PD-1/PD-L1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this